KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Current Assets (2018 - 2025)

Vir Biotechnology's Current Assets history spans 8 years, with the latest figure at $514.1 million for Q4 2025.

  • On a quarterly basis, Current Assets fell 50.69% to $514.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $514.1 million, a 50.69% decrease, with the full-year FY2025 number at $514.1 million, down 50.69% from a year prior.
  • Current Assets hit $514.1 million in Q4 2025 for Vir Biotechnology, down from $545.7 million in the prior quarter.
  • Over the last five years, Current Assets for VIR hit a ceiling of $2.6 billion in Q1 2022 and a floor of $514.1 million in Q4 2025.
  • Historically, Current Assets has averaged $1.5 billion across 5 years, with a median of $1.2 billion in 2024.
  • Biggest five-year swings in Current Assets: surged 165.37% in 2022 and later tumbled 50.69% in 2025.
  • Tracing VIR's Current Assets over 5 years: stood at $1.6 billion in 2021, then skyrocketed by 61.19% to $2.5 billion in 2022, then plummeted by 36.95% to $1.6 billion in 2023, then tumbled by 34.36% to $1.0 billion in 2024, then tumbled by 50.69% to $514.1 million in 2025.
  • Business Quant data shows Current Assets for VIR at $514.1 million in Q4 2025, $545.7 million in Q3 2025, and $735.7 million in Q2 2025.